ABOUT US A company that sees schizophrenia treatment differently
Minerva is focused on restoring key aspects of quality of life for people living with schizophrenia by addressing one of the most disabling aspects of the disorder: negative symptoms.
The effects of negative symptoms, which include loss of motivation, anhedonia, and emotional blunting, can prevent patients from maintaining relationships, attending school, holding a job, and other rewarding aspects of day-to-day life.
We are advancing roluperidone (MIN-101) as a monotherapy designed specifically to target these symptoms, which have historically received less attention in schizophrenia treatment.
Supported by multiple randomized controlled trials, we have the only investigational medicine to demonstrate the ability to significantly improve these primary negative symptoms.
OUR MISSION
To enable people with schizophrenia to re-engage in their lives, communities, and society as a whole.
OUR TEAM
We are driven by the large areas of unmet need in CNS disorders including the lack of available treatments for the primary negative symptoms of schizophrenia. Our team brings deep expertise in neuropsychiatry, clinical pharmacology, and CNS drug development, as well as a shared commitment to turning that science into tangible change for patients.
BOARD OF DIRECTORS
scientific advisory board
Boehringer Ingelheim (retired)
COLLABORATIONS
Transformational progress requires collaboration. We partner with biopharma partners, clinicians, and patient advocacy organizations who share our commitment to ushering in a new era in schizophrenia care.
